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Background: Diabetes and particularly high blood glucose levels are implicated in neurodegeneration. One of the
hallmarks of neurodegeneration is protein aggregation. We investigated the presence of protein aggregation in the
frontal brain of Zucker diabetic fatty (ZDF) rats, an animal model for diabetes. Further, the effect of NaHS in
suppressing protein aggregation in cultured brain slices from ZDF was assessed.
Results: The levels of protein synthesis, protein/gene expression, autophagy and anti-oxidant defense were
evaluated in ZDF and control (Lean) brains.
Compared to Lean, ZDF brains displayed a significant increase in protein aggregates, p-tau, fibronectin expression
and protein glycosylation. Increased phosphorylation of mTOR and S6 ribosomal protein in ZDF indicated higher
protein synthesis, while the increase in ubiquitinated proteins and LC3-I in ZDF brains accompanied by lower LC3-II
expression and LC3-II/LC3-I levels indicated the blockage of proteolytic pathways. CBS (cystathionine beta synthase)
protein and mRNA expression and thiol group levels in ZDF brains were lower compared to Lean. ZDF brains show
a higher level of reactive oxygen species. In vitro NaHS treatment normalized proteostasis while counteracting
oxidative stress.
Conclusion: Our data demonstrate increased protein synthesis and aggregation in the diabetic ZDF rat brain,
which was reversible by NaHS treatment.
This is the first report on the potential use of NaHS as a novel strategy against protein aggregation in
diabetic brain.
Keywords: Autophagy, ZDF rats, Protein aggregates, Cystathionine beta synthase, Carboxymethyllysine, NaHS,
Fibronectin, Reactive oxygen species, mTORBackground
Impairment of cognitive function is a feature that has
been observed in diabetes, especially in type II diabetic
patients [1,2], although the relationship remains dis-
puted. Increased glycated hemoglobin 1 (HbA1c), indi-
cating increased average blood glucose levels over a
longer period, is related to lower cognitive function in* Correspondence: Talaei@irimc.org
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reproduction in any medium, provided the orindividuals with type 2 diabetes and the decline in gly-
cemic control is related to lower scores on cognitive
function tests [3]. In turn, this is in accordance with the
finding of advanced glycation end-products (AGEs) in
dementia and diabetic microvascular disease, in which
decreased cerebral glucose metabolism is observed [4].
Indeed, low rates of glucose metabolism in brain cells
lead to the accumulation of glycoproteins associated
with subsequent formation of cytotoxic aggregates in
brain [5]. Animal experiments also suggest a relationship
between diabetes and cognitive impairment, as observedtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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or db/db mouse [6] and in type 1 diabetic models of
streptozotocin-induced diabetes mellitus in rat [7] and
mouse [8]. As neurodegenerative diseases are often char-
acterized by defects in brain protein maintenance [9], we
employed an inbred model for type 2 diabetes the fa/fa
Zucker diabetic fatty (ZDF) rat to study the effects of
high glucose concentration on protein expression in
brain. Moreover, there is still a lack of strategies to in-
hibit diabetes induced toxic protein aggregate formation
in tissues which could be to some degree answered by
our research.
Protein aggregate formation affects cellular function
and has been implicated in various aging related disor-
ders [10] and complications [11]. Protein aggregation is a
common feature of neurodegenerative diseases leading to
neurofibrillary tangle formation with cognitive deficits
[12], including Alzheimer’s, Parkinson’s and Huntington’s
disease, amyotrophic lateral sclerosis, frontotemporal de-
mentia, ataxias, and human prion diseases. In many neu-
rodegenerative complications such as Alzheimer’s, these
tangles contain PHF (paired helical filaments) which are
highly insoluble structures, composed of a highly phos-
phorylated form of the microtubule-associated protein
tau. Although the characterization of brain protein aggre-
gation is still insufficiently reported in type 2 diabetes,
the close similarity in protein aggregate formation be-
tween Diabetes and Alzheimer’s may indeed indicate
that the two conditions share key mechanistic targets
[13]. It has been suggested that mTOR (mammalian tar-
get of rapamycin), which is an established component in
proteostasis known to be implicated in different neuro-
degenerative complications [14], may represent an im-
portant link between nutrient excess with obesity and
insulin resistance and their possible complications [15].
Although mTOR is an important regulator of neuronal
development and function, including tau expression [16],
to date only few studies have addressed a possible impli-
cation of mTOR in diabetes in relation to protein aggre-
gate formation in brain tissue. Considering the induction
of mTOR by high glucose levels [17], the mTOR pathway
is likely implicated in the induction of brain protein
aggregation in diabetes [18]. The presence of oxidative
stress due to reactive oxygen species (ROS), and in-
creased protein glycosylation leading to protein-protein
crosslinking or aggregation [19] might be additional
factors involved.
Different mechanisms deal with misfolded proteins
to prevent the accumulation of aggregates. One such
mechanism is autophagy, which removes ubiquitinated
misfolded protein aggregates. In the light of possible
mTOR activation (see above) [20], autophagy may be
inhibited by phosphorylation of ribosomal protein S6,
a main downstream effector of mTOR [21]. In addition,degradation by the ubiquitin-proteasome system seems in-
volved in the clearance of misfolded proteins, especially
oxidative stress induced ubiquitinated (UB) proteins
that are resistant to breakdown via autophagy and ubi-
quitin routes [22]. Although acute oxidative stress in-
duces autophagy [23], it is still conceivable that in
diabetes the chronically increased levels of glucose may
lead to imbalances in the antioxidant capacity within
the cell. In turn, this would result in oxidative stress-
mediated injury [24] which may impair autophagic
clearance routes as observed in cells cultured at high
glucose concentrations [25], thus further contributing
to the formation of highly insoluble aggregates.
Another defense mechanism against protein aggregate
formation constitutes of brain antioxidants such as
FABP, thiol groups or H2S which would restrict oxida-
tive damage by high glucose concentrations. It is known
that pyridoxamine, an antioxidant and allosteric activa-
tor of the H2S producing enzyme cystathionine beta
synthase (CBS) inhibits AGE formation [26] and pro-
tects cells from oxidative damage [27]. We have previ-
ously shown that H2S, as NaHS, modulates mTOR
pathway in aging Werner syndrome skin fibroblasts and
inhibits protein aggregation and aging phenotype while
diminishing oxidative stress [28]. Further H2S has been
also shown to induce protective autophagy in colon epi-
thelial cells [29]. Nevertheless, the effect of H2S on in-
hibition or reversal of protein aggregation has yet not
been studied in diabetic brain.
The first aim of this study was to identify diabetes in-
duced protein aggregation in brain tissue obtained from
an animal model of diabetes mellitus type 2. As frontal
brain is implicated in cognitive behavior [30], we estab-
lished the nature of protein aggregates in this brain re-
gion in 17 weeks old Zucker diabetic fatty rats (ZDF)
compared to age matched Lean controls, and explored
proteostasis routes. As we found changes in brain pro-
teostasis to coincide with lower levels of brain thiol
groups and diminished expression of CBS in ZDF, we
sought as a second aim to investigate a potential benefi-
cial effect of H2S. However, others have previously
demonstrated that administration of H2S (as NaHS) in-
fluences glycemic control in vivo thus changing blood
glucose and HbA1c levels [31,32]. Therefore, we exam-
ined the effect of NaHS treatment on proteostasis in
cultured brain tissue slices to assess the direct effects of
H2S on brain, while excluding confounding effects of
the modulation of glycemic control.
Results
HbA1c and glucose concentrations
Development of diabetes in ZDF was monitored by meas-
urement of HbA1c, glucose and body weight (Table 1).
Body weight of ZDF animals was significantly increased
Table 1 Development of diabetes in ZDF (zucker fatty rat) was monitored by measurement of HbA1c, glucose and
body weight
Wk 7 Wk 9 Wk 11 Wk 13 Wk 15 Wk 17
Glucose (mmol/l)
Lean 7.8±0.4 8.9±0.1 8.3±0.2 8.3±0.2 8.5±0.3 8.3±0.2
ZDF 9.2±1.4* 9.9±0.6* 9.2±0.4* 9.6±0.4* 10.6±1.0* 11.0±1.0*
HbA1c (%)
Lean 2.9±0.01 3.4±0.02 3.4±0.05
ZDF 3.3±0.04* 4.8±0.13* 5.0±0.24*
Body weight (g)
Lean 211±5 247±4 280±3 317±5 314±6 365±5
ZDF 252±7* 332±9* 395±7* 449±5* 486±7* 504±9*
Body weight, HbA1c levels, and blood glucose levels are significantly increased in ZDF compared to Lean rats as measured in week 7 to week 17.
* < 0.05 = different from controls (Lean) at the same stage.
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examined. Moreover, the increase in body weight of ZDF
animals between week 7 and 17 (100 ± 4% (p < 0.05)) was
27% higher compared to the increase observed in Lean an-
imals between week 7 and 17 (73 ± 2% (p < 0.05)). The im-
pairment of glycemic control in ZDF animals was
evidenced by both significantly higher blood glucose and
HbA1c levels compared to Lean at all time points exam-
ined. At week 17 in ZDF the percent difference to Lean
amounted to 25 ±0.5% and 30 ±0.4% (p < 0.05) for blood
glucose and HbA1c respectively. The increase in blood glu-
cose of ZDF animals between week 7 and 17 (19 ± 2% (p <
0.05)) was 13% higher compared to the increase observed
in Lean animals between week 7 and 17 (6 ± 0.5% (p <
0.05)). In addition, the increase in HbA1c level of ZDF ani-
mals between week 7 and 17 (50 ± 2% (p < 0.05)) was 33%
higher compared to the increase observed in Lean animals
between week 7 and 17 (17 ± 3% (p < 0.05)). Finally, the
glucose concentration in the brain homogenates of the
ZDF group (2.9 ± 0.7 mmol/kg) was found to be signifi-
cantly higher than in the Lean group (1.3 ± 0.1 mmol/kg,
p < 0.05). Together, these data demonstrate significantly
impaired glycemic control in ZDF, yet without the full
blown development of overt diabetes type 2.
Protein aggregates, tau and fibronectin expression
The silver stain showed a doubling of the number of
protein aggregates present throughout the frontal brain
in ZDF (Figure 1A). The aggregates were seen as black/
brown entities with a tangled conformation (Figure 1C).
To further substantiate increased protein synthesis in
ZDF brains, the ratio of protein-to-DNA was measured.
This ratio was significantly increased in ZDF brains
showing higher protein synthesis levels in ZDF brains
(Figure 1B). The expression of tau and fibronectin were
investigated by Western blot analysis and qPCR analysis.
Tau protein levels were increased in ZDF brains comparedto Lean (Figure 1D). Especially tau protein isoforms with
molecular weights around 55 and 65 kDa [33] were
increased in frontal sections of ZDF compared to Lean
(Figure 1D). In immunohistochemistry analysis, tau pro-
tein was seen as black/brown entities with an intact pat-
tern in Lean brain but a dispersed pattern in ZDF brain
(Figure 1F), which may suggest the cleavage of tau protein
in ZDF. Total tau mRNA levels also showed a two times
increase in ZDF brains (Figure 1E). Fibronectin protein
expression was investigated because of its higher level of
expression in diabetes [34] and also its presence in neuro-
degenerative diseases [35]. We observed that fibronectin
protein in frontal brain of ZDF was about 3 times higher
compared to Lean (Figure 1G). This was also confirmed by
immunohistochemistry analysis of brain tissue (Figure 1I).
Fibronectin mRNA levels were also found to be 3 times
higher in ZDF brains compared to Lean (Figure 1H).
Proteostasis components
Increased expression of proteins such as tau and fibro-
nectin in the face of aggregate formation may denote de-
railment of proteostasis in neurons. Therefore, we
examined activation of the mTOR pathway as a major
route controlling protein synthesis, as well as protein
degradation by autophagy and ubiquitylation. ZDF brain
demonstrated an increased expression of mTOR and
phosphorylation of mTOR (p-mTOR serine 2448) in ZDF
(Figure 2A). Next, we examined ribosomal protein S6
(S6), being the immediate downstream target of the
mTORC1 pathway conveying increased protein synthe-
sis. In brain of ZDF, expression of both S6 and phos-
phorylated S6 (p-S6) was markedly elevated compared to
Lean (Figure 2B). The ratios of the phosphorylated forms
of mTOR and S6 ribosomal protein over the total ex-
pression of these proteins in brain was increased for
both mTOR (Figure 2C) and S6 (Figure 2D) in ZDF
brains, disclosing the activation of the mTOR pathway.
Figure 1 Excess protein aggregation in the frontal brain of ZDF
(zucker diabetic fatty rat) compared to Lean. (A) ZDF brain
shows doubling of the expression of protein aggregates (tangles).
(B) Higher protein synthesis levels in ZDF brains indicated by higher
protein/DNA ratio. (C) ZDF brain shows increased number of
neurofibrillary tangles. Silver staining depicts tangles in dark brown/
black elements with a diameter of 10–20 μm as magnified in top
inset. (D) ZDF displays increased levels of tau proteins as found by
Western blotting. (E) Real-time PCR analysis of the mRNA expression
of total tau relative to β-actin. (F) ZDF displays increased levels
of tau protein isomers and tau protein cleavage as found by
immunohistochemistry (indicated by →). (G) ZDF displays increased
levels of fibronectin as found by Western blotting. (H) Real-time
PCR analysis of the mRNA expression of fibronectin relative to
β-actin. (I) Immunohistochemistry analysis shows higher fibronectin
expression in ZDF rats in comparison with Lean (indicated by →).
Magnification 40×, Data are Means ± SEM (n≥ 5 per group),
* <0.0001 (difference to control gray bars in each group); unpaired
t-test. Western blot expression is normalized to β-actin; lanes of
western blot insets are in the same order as in the X-axis.
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tubule-associated protein 1 light chain 3) was performed.
ZDF rats showed an increased expression of LC3-I, with
lower expression of LC3-II compared to Lean (Figure 2E).
The ratio of LC3-II-to-LC3-I in ZDF brains is halved
compared to Lean brain showing lower autophagy levels in
ZDF brains (Figure 2F). Also, ZDF brains showed increased
levels of mono- and polyubiquitinated proteins (Figure 2G).
Collectively, these data substantiate the impairment of pro-
teostasis in ZDF brain consisting of increased protein
synthesis and degradation via the proteosomal route ac-
companied by lower autophagy levels.Glycosylation and reactive oxygen species damage
Diabetes is associated with increased ROS (Reactive oxygen
species) production, part of which is explained by glycosyl-
ated protein species inhibiting the electron transport chain
of mitochondria [36]. Indeed, ZDF brain showed a slight,
but significantly increased level of carboxymethyllysine
(CML), indicating the presence of glycosylated protein spe-
cies (Figure 3A). Moreover, HIF1A (Hypoxia inducible
factor 1) levels, known to be upregulated through ROS
formation [37], were increased in ZDF brains (Figure 3B).
Also, ZDF brain showed a lower expression of FABP
(Figure 3C), a protein depleted by ROS damage. Further, a
fluorogenic probe was used to assess the formation of ROS
in brain tissue. ROS formation in brain homogenate was
doubled in ZDF compared to Lean (Figure 3D).Brain CBS expression and thiol group content
Expression of CBS (H2S producing enzyme) and brain thiol
groups were assessed in brain to evaluate the antioxidant
defense levels. CBS protein expression (Figure 4A), CBS
Figure 2 mTOR pathway activity, autophagy and protein ubiquitination in brain of ZDF (zucker diabetic fatty rat). (A) Increased
expression of mTOR and its phosphorylated form in ZDF detected by an antibody raised against phosphorylation on serine 2448. (B) Increased S6
ribosomal protein (S6) and its phosphorylated form (p-S6) in ZDF. (C) Increased mTOR activity in ZDF. (D) Increased S6 protein activity in ZDF. (E)
Increased expression of LC3-I and the decrease in LC3-II levels in ZDF. (F) Autophagy levels are lower in ZDF compared to Lean as shown by
LC3-II/LC3-I ratio. (G) Increased levels of mono- and polyubiquitinated proteins in ZDF. Insets: typical examples of Western blot data showing
protein of interest (upper part) and β-actin (lower part). Data are Means ± SEM (n ≥ 5 per group), * <0.0001 (difference to control gray bars in each
group); unpaired t-test. Western blot expression is normalized to β-actin; lanes of western blot insets are in the same order as in the X-axis.
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were found to be significantly lower in ZDF brain com-
pared to Lean.NaHS treatment diminishes protein aggregation
To examine the pharmacological potential of H2S in
counteracting the defective proteostasis in ZDF brains
Figure 3 Oxidative stress and damage in brains of ZDF rats. (A) Expression of CML/AGE is increased in ZDF compared to Lean. (B) HIF1A
expression is higher in ZDF brain compared to Lean. (C) FABP is 3 times lower in ZDF rats compared to Lean. D) ROS formation is higher in ZDF
brains compared to Lean. ROS formation is measured by the level of Fluorescin fluorescence. Western blot data showing protein of interest
(upper part) and β-actin (lower part). Data are Means ± SEM (n≥ 5 per group), * <0.0001 (difference to control gray bars), unpaired t-test. Western
blot expression is normalized to β-actin; lanes of western blot insets are in the same order as in the X-axis.
Talaei et al. BMC Cell Biology 2014, 15:1 Page 6 of 16
http://www.biomedcentral.com/1471-2121/15/1while excluding the beneficial effects of H2S in lowering
glucose concentrations in the whole animal [31], H2S
was administered to cultured brain slices. To this end
we used culture medium with 35 mM of glucose, as ini-
tial experiments had shown that the normal medium
(25 mM glucose) diminishes protein aggregation in brain
(data not shown). To this end, slices of ZDF brain were
treated with 50 μM NaHS every 10 h for two days. Brain
slice viability and apoptosis was substantiated by MTSFigure 4 Thiol groups and CBS (cystathionine beta synthase) express
CBS expression is lower in ZDF brains. (B) Real-time PCR analysis of the exp
lower than Lean. Western blot data showing protein of interest (upper part
* <0.0001 (difference to control gray bars), magnification 40×; unpaired t-te
blot insets are in the same order as in the X-axis.and caspase 3/7 assays (Figure 5). Cultured brain slices
retained protein aggregates (Figure 6A). The number of
aggregates was doubled in ZDF brain slices compared to
Lean. Treatment of ZDF brain slices with NaHS, how-
ever, reduced the number of aggregates to Lean levels
(Figure 6B). N-acetyl cysteine (NAC) lowered the number
of aggregates but to a lower degree compared to NaHS
(Figure 6A-B). Further, protein synthesis level was substan-
tiated by calculating the ratio of protein-to-DNA. This ratioion in ZDF (zucker fatty diabetic rat) and Lean frontal brain. (A)
ression of CBS relative to β-actin, and (C) Thiol group level in ZDF is
) and β-actin (lower part). Data are Means ± SEM (n≥ 5 per group),
st. Western blot expression is normalized to β-actin; lanes of western
Figure 5 Tissue viability (MTS assay) and apoptosis (caspase 3/7 activity) in cultured brain slices. Left panel: Cells dissociated from two
days NaHS treated ZDF slices show the highest level of viability with the lowest levels of apoptosis compared to cells in slices from Lean and
ZDF or the fully viable non-cultured slices which show 100% viability. Right panel: Cells dissociated from the untreated ZDF slices show the
highest caspase activity in culture, which is decreased below the level of Lean by treatment with NaHS. Data are means ± SEM (n ≥ 5 per group),
* = different from control gray bars, * < 0.05; One way ANOVA.
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synthesis levels in ZDF, while NaHS counteracted this in-
crease showing inhibitory properties on protein synthesis
(Figure 6C). A similar pattern of decrease through NaHS
treatment was also found for the other markers. The
65 kDa tau species expression was 3-fold higher in ZDF
slices compared to Lean and NaHS treatment was found to
normalize tau expression in ZDF brain (Figure 6D). Further,
hyperphosphorylated tau, as detected by the AT8 antibody,
was present at 70 kDa in ZDF brains which was decreased
by NaHS treatment (Figure 6D). Also, fibronectin expres-
sion was doubled in ZDF compared to Lean and was nor-
malized by NaHS treatment (Figure 6E).
The levels of total tau mRNA (Figure 6F) and fibro-
nectin mRNA (Figure 6G) was higher in ZDF brains
compared to Lean and this increase in mRNA levels was
counteracted and lowered to below mRNA levels present
in Lean brains.
The phosphorylation of mTOR and S6 ribosomal pro-
tein was 4 times higher in cultured brain slices from
ZDF and both were lowered to normal levels by NaHS
treatment (Figure 7A,B). Also the total levels of mTOR
(Figure 7A) and S6 ribosomal protein (Figure 7B) were
higher in ZDF and were lowered to below the expression
observed in Lean brains by NaHS treatment. The ratios
of the phosphorylated forms of mTOR and S6 ribosomal
protein to the total expression of these proteins in each
sample show activation of mTOR (Figure 7C) and S6
ribosomal protein (Figure 7D) in ZDF brains which is
fully counteracted by NaHS treatment. LC3-I expression
was 2 times higher in ZDF rat brain slices and its level
was decreased through NaHS treatment (Figure 7E). The
ratio of LC3-II-to-LC3-I in ZDF brains was two times
lower compared to Lean brains showing lower autophagy
levels in ZDF brains. NaHS strongly increased autophagylevels in ZDF brains (Figure 7F). Mono- and polyubiqui-
nated protein expression was 3 times higher in ZDF brains
and was also lowered to Lean levels by NaHS treatment
(Figure 7G).
HIF1A expression was not found different between
ZDF and Lean brains in vitro, but NaHS increased the
expression of this protein in ZDF (Figure 8A). FABP ex-
pression was reduced in ZDF brain slices compared to
Lean. NaHS treatment of ZDF brains did not affect
FABP expression (Figure 8B). The assessment of ROS
levels shows that treatment of Lean at high glucose con-
centrations did not change ROS levels. ROS production
in ZDF brains was inhibited by the addition of NaHS or
NAC (Figure 8C).
Peroxiredoxin (Prx) enzyme modulates oxidative stress
via its evolutionary conserved cystein (Cys) residues. Under
oxidative stress condition, cystein sufinic acid of Prx be-
comes oxidized. To further study the potential oxidation of
Prx enzymes under oxidative stress in ZDF brain, we per-
formed Western blot analysis with oxidized Prx specific
antibody, anti-Prx-SO3 in all samples. Our results show
that Peroxiredoxins is highly oxidized in ZDF brain and
that NaHS and NAC reverse this process (Figure 8D).
Thus, NaHS might be counteracting the defective pro-
teostasis and protein aggregation in cultured ZDF brain
slices through reduction in protein synthesis and inhib-
ition of oxidative tress.
Discussion and conclusion
Our data demonstrate the increase in protein aggregates
in brain of ZDF rats probably due to a derailment in pro-
tein homeostasis, which was reversed in vitro by treatment
with NaHS. It appears that several factors might be con-
tributing to protein aggregation in ZDF brains. First, pro-
tein synthesis is enhanced, as evidenced by the increase in
Figure 6 (See legend on next page.)
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Figure 6 Treatment with NaHS counteracts protein aggregates in cultured brain slices from ZDF (zucker diabetic fatty rat). (A) ZDF
brain slices retain protein aggregates in culture. Protein aggregates are diminished through NaHS treatment. NAC diminishes protein aggregates
in ZDF. (B) The doubling of the number of aggregates in ZDF brain slices is lowered to Lean levels by NaHS treatment. NAC lowers protein
aggregates in ZDF brain but at a much slower rate. (C) NaHS lowers the higher protein synthesis levels in cultured ZDF brains indicated by
higher protein/DNA ratio. (D) 65 kDa and 55 kDa tau expression is three times higher in ZDF rats compared to Lean and NaHS treatment
normalizes tau levels. Also, hyperphosphorylated tau (AT8) is increased in ZDF brains and normalized by NaHS. (E) Fibronectin expression is
doubled in ZDF rats compared to Lean and is normalized by NaHS treatment. (F) Real-time PCR analysis of the expression of total tau relative
to β-actin. NaHS lowers total tau expression in ZDF to lower than Lean levels (G) Real-time PCR analysis of the expression of fibronectin relative
to β-actin. NaHS lowers fibronectin expression in ZDF to lower than Lean levels. Western blot data showing protein of interest (upper part) and
β-actin (lower part) from the same samples. Data are means ± SEM (n≥ 5 per group) *, #, + <0.05 = statistically different, * different from control
gray bars in each group, # different from ZDF group, + different from lean, ZDF and ZDF + H2S; One way ANOVA. Western blot expression is
normalized to β-actin; lanes of western blot insets are in the same order as in the X-axis.
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ZDF brains. Further, the loss of proper defense against the
increased oxidative stress seems to be involved, as demon-
strated by decreased levels of FABP, thiol levels and CBS
and higher amounts of glycosylated proteins in ZDF. Fi-
nally, the clearance mechanisms for deviant proteins seem
impaired, as demonstrated by the excess of ubiquitinated
proteins (UB-proteins) and a relative impairment of au-
tophagy in ZDF. The exact order and contribution of these
factors in ZDF is hard to unravel. Yet our experiments in
brain slices cultured under increased glucose conditions
suggest that the loss of oxidant defense has an important
role, as aggregates from ZDF were abolished by treatment
with NaHS, which is known to be a strong cytoprotective
antioxidant [27,38]. In addition, we also found NaHS to
inhibit the mTOR pathway and the resulting inhibition of
protein synthesis is likely contributing to the beneficial ef-
fects of NaHS on protein aggregation. Together, our re-
sults suggest that diabetes induces protein aggregation in
brain of ZDF rats and could potentially provide a basis for
possible therapeutic strategies in cognitive disorders re-
lated to protein aggregation.
Our data disclose the presence of protein aggregates in
ZDF brains. Tau and its hyperphosphorylated form (rec-
ognized by AT8 antibody) is one of the main neuronal
proteins involved in protein aggregation [39] and has
been implicated in the loss of cognitive performance
[39]. Hyperphosphorylated tau (p-tau) has been observed
previously in the brain of mice models of type 1 and 2
diabetes [40]. Importantly both p-tau [41] and protein
aggregates have been found in the brain of streptozoto-
cin (STZ) induced mouse model of type 1 diabetes [42].
Thus, the increased total tau mRNA together with phos-
phorylation of tau protein in ZDF rat brains, might
cause impairment in cellular function and cognitive dis-
orders [43]. Tau hyperphosphorylation in diabetes might
be due the tau protein cleavage inducing toxic tau aggre-
gation. Indeed, we observed a dispersed pattern of tau
protein staining, which might suggest the cleavage of tau
protein in ZDF brain, consistent with a recent report sug-
gesting that tau cleavage is an early event in aggregatepathology [44]. Possibly, high glucose is implicated in ROS
formation [45] and the increase in tau cleavage and phos-
phorylation might be secondary to the chronic presence of
ROS in diabetes [46]. The increase in advanced glycation
end-products (AGEs) due to protein glycation in ZDF, as
exemplified by the increased CML expression, may consti-
tute a core for protein aggregation and probably underlie
the process of cognitive decline [47]. High glucose is im-
plicated in the increase in CML in ZDF brains [48] and
the increase in fibronectin, a component of extracellular
matrix, we observed, may also be due to higher glucose
levels and the subsequent excessive ROS formation, as
found previously in astrocytes [49].
Our data implicate that several changes in proteostasis
might underlie protein aggregate formation in ZDF brains.
We found both the expression and phosphorylation of
mTOR and S6 ribosomal protein to be higher in ZDF
brains. Phosphorylation of these proteins is necessary for
protein synthesis. High glucose is known to stimulate
mTORC1 to promote protein synthesis [50], which may
represent one of the main causes of protein aggregate for-
mation in ZDF brain. Indeed, mTOR inhibitors such as
rapamycin protect against aggregate formation in taupa-
thies [51]. In addition to mTOR activation, changes in the
two major intracellular protein degradation systems, the
autophagy-lysosomal and ubiquitin-proteasome system
[52] were observed. Our data suggest a blockade in the au-
tophagy pathway, thus limiting protein turnover, in ZDF
brain in view of the absence of transition of LC3-I into
LC3-II. Such blockade in autophagy is in line with the
results in Alzheimer’s models, in which the induction of
autophagy is known to lead to a massive accumulation
of autophagy intermediates (vacuoles) with low levels of
clearance [53] along dystrophic and degenerating neurites.
In addition to its effect on autophagy, proteosomal break-
down of proteins seems also affected, as ZDF had higher
expression of ubiquitinated proteins (UB-proteins), which
normally are processed by proteosomal degradation [54].
UB-protein aggregates increase in hyperglycemia and endo-
plasmic reticulum stress [19] and get accumulated in neur-
onal inclusions [55]. Curiously, UB-proteins accumulated in
Figure 7 (See legend on next page.)
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Figure 7 Treatment with NaHS modulates protein synthesis and degradation pathways in cultured brain slices from ZDF (zucker
diabetic fatty rat). (A) The expression of mTOR and its phosphorylated form (p-mTOR2448) is higher in ZDF and is lowered to normal levels by
H2S treatment. (B) The expression of S6 protein and its phosphorylated form (p-S6 ribosomal protein) is higher in ZDF rats and is normalized by
NaHS treatment. (C) Increased mTOR activity in ZDF is counteracted by NaHS. (D) Increased S6 protein activity in ZDF is counteracted by NaHS.
(E) LC3-I is higher in ZDF brains while LC3-II shows lower expression. NaHS lowers LC3-I expression. (F) Autophagy levels are lower in cultured
ZDF slices compared to Lean as shown by LC3-II/LC3-I ratio. NaHS increases autophagy levels in ZDF. (G) Mono- and polyubiquitinated protein
expression is 3 times higher in ZDF brains compared to Lean and is lowered to normal by NaHS. Western blot data showing protein of interest
(upper part) and β-actin (lower part) from the same samples. Data are means ± SEM (n≥ 5 per group), * < 0.05 = different from control gray bars
in each group; One way ANOVA. Western blot expression is normalized to β-actin; lanes of western blot insets are in the same order as in the X-axis.
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http://www.biomedcentral.com/1471-2121/15/1ZDF brains had a lower molecular weight compared to
Lean, which might reflect the increased protein cleavage in
ZDF brain. Taken together, in ZDF brains the protein syn-
thesis machinery is activated while protein degradation is
impaired, likely becoming the leading cause in the forma-
tion of protein aggregates.Figure 8 NaHS counteracts oxidative stress and damage in brain slice
but NaHS increases the expression of this protein. (B) FABP expression is d
production is twice higher in ZDF brains compared to Lean. NaHS an NAC
formation is measured by the level of Fluorescin fluorescence. (D) The oxid
reversed to non-oxidized form through NaHS and NAC treatment. Western
part) from the same samples. Data are means ± SEM (n ≥ 5 per group), * <
expression is normalized to β-actin; lanes of western blot insets are in theROS damage to proteins exists in brain cells at high
glucose levels [45,56] likely representing a second driv-
ing force for protein aggregation in diabetes. The pres-
ence of increased ROS in ZDF brain is evidenced by the
decrease in FABP, and the increases in HIF1A and ROS
production. Further, the increase in CML indicatess of ZDF rats. (A) HIF1A expression is similar in ZDF and Lean brains
ecreased in ZDF and is unaffected by NaHS treatment. (C) ROS
(N-acetyl-L-cysteine) inhibit ROS formation in ZDF slices. ROS
ized forms of Peroxiredoxins is twice higher in ZDF brain and is
blot data showing protein of interest (upper part) and β-actin (lower
0.05 = different from control gray bars; One way ANOVA. Western blot
same order as in the X-axis.
Table 2 Summary of changes in several important
parameters involved in high glucose induced protein
aggregation in ZDF brain and the effect of NaHS on them
Parameters analyzed ZDF brain NaHS + ZDF brain
ROS levels ↑ ↓
Protein aggregates ↑ ↓




CML expression ↑ ↓
UB-proteins ↑ ↓
Autophagy ↓ (LC3-II↓, LC3-I↑) ↑ (LC3-II↓, LC3-I↓)
Tau and p-tau ↑ ↓
Fibronectin ↑ ↓
ZDF brain was compared to lean brain as control and NaHS treated ZDF brain
was compared to ZDF brain as control. The arrows indicate the changes in
each parameter.
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http://www.biomedcentral.com/1471-2121/15/1impaired glucose metabolism and formation of oxidized
amino acids in ZDF brains [48]. Thus, our results dem-
onstrate that ROS production is likely increased in brain
of ZDF rats. Oxidative stress might precede protein de-
position [57], but conversely protein aggregates may also
increase ROS formation and damage brain cells through
oxidization of neuronal components [58] eventually
leading to apoptotic or necrotic cell death [5]. Thus, a
suitable antioxidant, potentially to some degree inhibits
the damage present at high glucose concentrations. Add-
itional loss of oxidant defense also would amplify the
detrimental effects of ROS. Amongst all the antioxidants
that are available in the body, thiols constitute the major
portion of the total body antioxidants and they play a sig-
nificant role in defense against reactive oxygen species
[59]. Here our data show for the first time that the levels
of CBS, one of the main H2S producing enzymes in brain,
and thiol content are significantly lower in ZDF brains.
Treatment with NaHS decreased protein aggregates in
cultured slices of ZDF frontal brain. Higher glucose
levels (35 mM) in culture medium provided a suitable
in vitro model for the experiments, first because accord-
ing to our previous experiment we found a lower glu-
cose level (25 mM) to diminish the number of protein
aggregates in vitro and second because higher glucose
levels are known to decrease H2S levels [60]. We have
previously shown that NaHS modulates mTOR activity
and inhibits ROS production in aging Werner syndrome
skin fibroblasts while inhibiting protein aggregation in
these cells [28]. Moreover, the induction of free thiol
groups in an organism might have an important role in
delaying the aging process [61]. This research is the first
report pointing to the therapeutic potential of H2S as
NaHS in protecting against protein aggregation in brain.
H2S may exert its protective effect through various
mechanisms. First, H2S possesses antioxidant properties
and administration of NaHS inhibits reactive oxygen
species, and the deposition of ECM (extracellular
matrix) components in diabetic rats [62]. Indeed, NaHS
treatment upregulated HIF1A in brain slices, potentially
protecting cells against oxidative stress while increasing
glucose tolerance/metabolism and mediating a neuro-
protective response [63]. Its important to note that accord-
ing to the presented data, having anti-oxidant properties is
not enough for a substance to lower protein aggregates in
ZDF brain to Lean levels, as NAC which is known to have
strong antioxidant activity, inhibited ROS formation but
did not show the full beneficial effects of NaHS in lowering
protein aggregates. Thus, these results suggest the presence
of additional mechanism involved in the beneficial action
of NaHS, although ROS inhibition is most probably an im-
portant factor. Secondly, H2S may act through inhibition
of the mTOR pathway. We found H2S to inhibit protein
synthesis by inhibition of mTOR as also shown previouslyin kidney cells [50]. A third mechanism of action of H2S
may constitute of regulation of autophagy. We found H2S
supplementation to regulate and lower LC3-I expression in
ZDF brain. H2S treatment led towards higher autophagy as
shown by LC3-II/LC3-I ratio. The increase in Sirt-1 levels
and Sirt-1 phosphorylation could be another important in-
dicator of higher autophagy levels through H2S treatment
[28]. As NaHS normalized proteostasis in ZDF brains by
inhibiting protein synthesis and gene expression, it would
be conceivable that the regulation of autophagy by H2S
represents a lowered flux of defective proteins to the
autophagy pathway. Finally, an effect of H2S on cellular
metabolism may convey beneficial effects in diabetes.
Hyperglycemia is known to inhibit AMP kinase (AMPK)
activity leading to cellular damage [64], H2S has the poten-
tial to preserve mitochondrial function [65] via regulation
of mitochondrial ATP-sensitive potassium channel, p38
mitogen-activated protein kinase and c-Jun NH(2)-ter-
minal kinase pathway. Consequently, H2S potentially con-
stitutes a suitable treatment against hyperglycemia
induced cell damage in case the above pathways are af-
fected [66]. Moreover, H2S has been shown to regulate
proteostasis in diabetic animals through activation of
AMPK [50]. Interestingly, H2S also potentiates the func-
tion of NMDA-glutamate receptors implicated in long
term memory, while protecting proteins against nitration
or oxidation [67]. Thus, H2S exerts different protective ef-
fects which seem to be of importance in the protection of
brain tissue from hyperglycemia stress and protein aggre-
gation. The changes in the expression of several proteins
probably involved in high glucose induced protein aggre-
gation in ZDF brain and the effect of NaHS on protein ag-
gregation and protein expression in ZDF brain are
summarized in Table 2.
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non-fasting blood glucose levels and HbA1c, it should be
noted that the development of overt diabetes was con-
siderably slower in this batch of ZDF than observed in
our previous experiments in the same animal strain [68].
While the reason for this remains elusive, in view of the
current data, the animals would be best defined as being
pre-diabetic.
This study identified the presence of protein aggregation
and its key mechanistic targets in ZDF brain and found it
to coincide with lowered brain thiol levels and lowered
CBS expression. In addition, we demonstrate for the first
time that the administration of H2S donor, NaHS, dimin-
ishes protein aggregation in the brain. Although we have
presented several hypothesis in regards to possible mech-
anism by which H2S inhibits protein aggregation in ZDF
brain, our goal here was not to establish a mechanism of
action for H2S treatment but rather to show that H2S in-
hibits protein aggregates in ZDF brains. This study pro-
vides further insight into beneficial effects of H2S which
may be exploited to protect the diabetic brain.
Methods
Animals, glucose measurement and sample preparation
Male Zucker diabetic fatty rats (ZDF, n = 8) and control
rats (Lean, n = 8) were obtained from Charles River
Laboratories at 6 weeks of age with an average weight of
266 g for ZDF and 203 g for Lean. The animals were fed
water and chow ad libitum throughout the experiment till
they reached 17 weeks of age. Blood samples were taken
every two weeks from week seven to week seventeen. Glu-
cose and HbA1c levels were measured by commercial kits
(Roche). At 17 weeks of age, rats were anesthetized by
2.5% isoflurane and sacrificed by exsanguination. Brains
were removed and either snap frozen in liquid nitrogen or
cut into 200 μm thick slices using a McIlwain tissue chop-
per and placed in brain nutrition medium/neurobasal
medium (Gibco BRL, Cat. No. 21103–049) for in vitro ex-
periments. The concentration of glucose in frontal brain
homogenates was measured using Accu-Check Aviva
(Roche diagnosis, Mannheim, Germany) in which a drop
of homogenized brain (n≥ 5 samples in each group) was
placed on the glucose test strip and read by the instru-
ment. All experiments were approved by the Animal Care
Committee of the University Medical Center Groningen
(Dec 6032B).
Brain section treatment
To study frontal brain slices in culture, 200 μm thick brain
slices were placed in brain nutrition medium/neurobasal
medium with 25 mM D-glucose and supplemented with
10% fetal bovine serum and 0.5 mM L-glutamine. As
higher glucose levels are suggested to be responsible for
the lower baseline levels of H2S detected in the medium ofcells [60] the above medium was supplemented to a total
of 35 mM glucose to create a high state of hyperglycemia,
an environment more similar to what is observed in vivo.
In treated slices, 50 μM NaHS was added to the wells
every 10 h until the completion of the experiment at two
days of culture. The final concentration of H2S in culture
medium after the addition of 50 μM NaHS lies in the nor-
mal range of brain H2S levels found in rats, i.e. between
50 and 160 μM [69]. In all our experiments, NaHS was
used at a concentration of 50 μM, as pilot experiments
showed this concentration to promote the highest level of
cell survival in cultured brain tissue sections according to
caspase 3/7 activity assay results, as also previously found
by others [69]. Controls did not receive NaHS in the
medium. NAC (N-acetyl-L-cysteine) 100 μM, which is the
highest achievable concentration in plasma with tolerable
oral dosing of NAC, was used to treat brain slices as add-
itional controls to study the effect of a frequently used
“antioxidant” in vitro, on ROS levels and protein aggrega-
tion in ZDF brains. Brain slices were kept in culture for
two days, washed with PBS (phosphate buffered saline)
and snap frozen in liquid nitrogen for either tissue staining
or Western blot analyses.
Antibodies and Western blot analysis
Antibodies used were mouse carboxymethyl lysine (R&D
system, MAB3247, UK), mouse mono- and polyubiquini-
lated conjugates (Enzo life Sciences BVBA, BML-PW1210-
0025), LC3 (Cell signalling, 2775), B-FABP (Santa Cruz
Biotechnology; FL-132; Sc-30088), fibronectin (Santa Cruz,
sc-6952), CBS (Santa Cruz SC-46830), phospho-mTOR
(Millipore 15–105 Pathway Explorer Anti-phospho-
mTOR ser 2448), p-S6 ribosomal protein (S235/236 Cell
Signaling D57.2.2E), S6 ribosomal protein (Cell Signaling
(5G10) 2217), HIF1A (Santa Cruz, sc-13515), total phos-
phorylation independent anti-tau (BR134, Cambridge,
UK), phosphorylated tau protein (AT8 Ser202/Thr205,
Innogenetics, Zwijndrecht, Belgium). Levels of hyperoxi-
dized peroxiredoxins were assessed by Western blotting
using rabbit anti-Prx-SO3 antibody (Abcam, ab16830).
Western blot analysis was conducted to investigate pro-
tein expression in brain tissue. Frozen frontal brains were
homogenized (20% w/v) in ice-cold RIPA lysis buffer (1%
Igepal ca-630, 1% SDS, Roche protease and phosphatase
inhibitor cocktail in PBS) [70]. The amount of protein was
measured by Bradford assay and loading buffer (20 μl) was
added to every 50 μg of protein and ran at 100 V for
70 min. Proteins were transferred to nitrocellulose mem-
branes. To use the same membranes to detect different
proteins and prevent possible loading interferences in pre-
sented data, the membranes were cut at specific places in-
dicated by colored protein ladder, using a sharp surgical
scalpel and probed using the appropriate antibody. Protein
bands on antibody treated and washed membranes were
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(supersignal), photographed by GeneSnap (version 6.07;
Syngene, Cambridge, UK) and analyzed with genetool
software (version 3.08, SynGene, UK). Protein expression
was corrected over β-actin as an internal reference.
Measurement of protein synthesis in brain tissue
To show the presence of active protein synthesis in ZDF
brain and the effect of NaHS treatment on protein synthe-
sis levels, the ratio of protein-to-DNA known as an indice
of protein synthesis capacity, was calculated in each sam-
ple. Total genomic DNA was isolated from each brain
sample using the Nucleospin Tissue Kit (Macherey-Nagel,
Duren, Germany). The DNA concentration in each sample
was measured using a NanoDrop spectrophotometer (Life
Science ND1000, US). Protein concentration in each sam-
ple was measured using the Bradford assay.
Real-time PCR (qPCR)
In addition to Western blot analysis, the expression of fi-
bronectin, tau and CBS in brain slices was analyzed by
qPCR. In brief, RNA was extracted from each sample
using the Nucleospin tissue kit (Cat NO. 740955.250
Macherey-Nagel, UK). RNA (1 μg) was reversely tran-
scribed in a reaction mixture (20 μl) containing 1 μl of
random hexamers, 0.5 μl of RNase inhibitor, deoxynu-
cleotide triphosphates (0.2 μl), 1 μl of reverse transcript-
ase, 4 μ l RT buffer and Tris buffer (pH 7.4) at 37°C.
Specific primers to rat Fibronectin (Forward: AGAGCA
TACCTCTCAGAG and Reverse: CTGCTCATCAGTTG
GGAA), rat total tau (Forward: TGACACGGACGCTG
GCCTGAA and Reverse: CACTTGGAGGTCACCTTG
CTC), Cystathionine beta synthase (Forward: ATGCTG
CAGAAAGGCTTCAT, Reverse: GTGGAAACCAGTC
GGTGTCT) and β-actin (Forward: AAGATGACCC AG
ATCATGTTTGAG and Reverse: ACGTACATGGCTGG
GGTGTTG) were synthesized (Base Clear, Netherland).
SYBER green qPCR was performed using Bio-rad CFX384
C1000 (USA, CA) and data were quantified by Bio-rad
CFX manager 2.0 using reagents from the SYBR Green
PCR-Master Mix (Qiagen, Hombrechtikon, Switzerland).
The samples in PCR 384 well plate were transferred to the
thermal cycler and applied to the following protocol: pre-
denaturation at 94˚C (5 min; 1 cycle) followed by 35 cycles
of denaturation at 94˚C (30s), annealing at 57˚C (30 s), ex-
tension at 72˚C (45 s) and a final extension at 72˚C
(8 min; 1 cycle), followed by a melting curve. All cycle
threshold (Ct) values were collected at the exponential
phase of the qPCR. All data were normalized to β-actin.
Histochemistry and microscopy
Flash frozen frontal brains were cut at 15 μm thick-
ness using a cryostat (Leica CM-1800, Chatsworth,
CA) at -20°C. Tissue sections were thaw-mounted ontoVistaVision HistoBond adhesive slides. The Bielschowsky
silver impregnation was performed to reliably stain protein
aggregates forming the neurofibrillary tangles [71]. To per-
form Bielschowsky silver stain, the rehydrated brain sec-
tions mounted on slides were covered with 20% AgNO3
and incubated at room temperature in the dark for
20 min. The solution was washed off with distilled water
and replaced by ammoniacal silver solution for 20 min in
the dark. Then, the solution was tipped off and the slides
were immersed in ammonia-water (four drops of ammo-
nia added to 100 ml distilled water). Subsequently, slides
were incubated in ammoniacal silver solution with devel-
oper (100 ml distilled water, 20 ml formaldehyde, 50 μl
concentrated HNO3 and 0.5 g citric acid) to develop the
silver stain for 3–6 min. The quality of stain was con-
trolled under the microscope (aggregates were dark
brown/black with cluster like conformation). The sections
were then immersed in ammonia water for 1 min and
then washed twice in distilled water. The reaction was
stopped using 5% hypo-sodium thiosulphate for 5 min.
Sections were rinsed, dehydrated, cleared and mounted by
resinous medium. Aggregates were counted in the frontal
brain sections. Ten random fields per slide of brain from
four animals in each group were examined.
For immunohistochemistry analysis the mounted sec-
tions on slides were subjected to graded ethanol rehydra-
tion (100–60%) and brought to water. Hydrogen peroxide
activity was blocked for 1 h in peroxidise-blocking buffer
(Dako, Denmark, S2023). The sections were then incu-
bated for 1 hr at 37°C with the primary antibodies (1:100
in PBS containing 1% BSA (bovine serum albumin) and
1% rat serum) at room temperature. The slides were
washed with PBS, followed by addition of the specific sec-
ondary antibodies either fluorescent or non-fluorescent
(1:100 in block buffer containing 1% BSA and 1% rat
serum) for 1 h at room temperature. Slides were then
washed in PBS thrice. Dako mounting medium was in-
corporated to visualize the nuclei and fix the glass cover-
slips on fluorescent stains. For non-fluorescent stains
AEC (3-Amino-9-Ethylcarbazole) +High sensitivity substrate
chromogen (Dako, Denmark k3469) was used to visualize
the stain while the nuclei were stained by hematoxylin
counter staining. Non-fluorescent stains were then washed
in tap water and coverslips were fixed using an aqueous
mounting medium (Dako).
Measurement of reactive oxygen species in brain
Oxygen radicals were determined by a fluorometric
method using fluorogenic CM-H2-DCFDA (2,7 dichlor-
oflourescein diacetate). 10 μl of each tissue sample in
RIPA was loaded into a 96-well FluoroNunc black Plate.
150 μl of 0.1 M phosphate buffer (pH 7.4) and 10 μl of
CM-H2-DCFDA (2,7 dichloroflourescein diacetate) in
methanol was added to each well. The plate was incubated
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12,000 × g for 8 min. Fluorescence was measured with a
Hitachi fluorescence spectrometer at an excitation wave-
length of 488 nm and an emission wavelength of 525 nm.
Auto fluorescence was subtracted prior to DCF fluores-
cence [72].
Assessment of intracellular thiol groups in brain
Total levels of cellular thiol groups (−SH) in Lean and
ZDF brain samples were measured based on the reduction
of 5,5 dithiobis-2-nitrobenzoic acid (DTNB, Sigma). Brains
were lysed in 10 mM Tris-buffer 1% Triton X-100 (Sigma),
followed by centrifugation at 7000 × g for 10 minutes. The
supernatant was incubated with phosphate buffer contain-
ing DTNB at room temperature for 60 minutes. The
quantification was conducted at 412 nm using a micro-
plate reader.
Statistical analysis
The statistical analyses was based on the analysis of ten
slices each from four animals using the One-way ANOVA
with Tukey’s test or unpaired student t-test with Welch’s
correction. Statistical significance difference was accepted
at P < 0.05 (GraphPad Prism version 5).
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